Lyric's $5B price tag tests whether healthcare software PE exits still clear at 20x

Reuters reported on Sept 9, 2026 that TPG is working with JPMorgan on a sale of Lyric that could value the company at roughly $5 billion, on about $250 million of annual EBITDA — a 20x multiple. That is more than 2x the ~9x implied when TPG paid $2.2 billion to carve ClaimsXten out of UnitedHealth Group in October 2022 and rebrand it as Lyric in April 2023. A clean 2.3x money multiple on entry, before any dividend recap, would be a respectable PE result — but only if the process actually clears at that price.

Lyric (formerly ClaimsXten) is a payment-integrity platform — software that decides whether a medical claim should be paid, edited or denied before money moves. Its website says nine of the top 10 U.S. health plans verify claims through Lyric before payment, the platform processes roughly 10 billion claim lines a year and is rated Best in KLAS 2025 for Pre-Payment Accuracy & Integrity. Under TPG it has bolted on ClaimShark (May 2025) and Concert AI (July 2026), extending into coordination-of-benefits and precision health payment accuracy. The revenue base is not disclosed, but at ~30–35% EBITDA margins the implied revenue run-rate from the EBITDA figure is roughly $700–800M — a number TPG has not confirmed publicly.

TPG's 20x ask sits well above what comparables are clearing right now. Waystar, the closest pure-play public comp, trades at roughly 14x EV/EBITDA on a $432M TTM EBITDA run-rate and a $6.04B enterprise value, on $1.21B of TTM revenue — a 5x EV/sales multiple that already prices in 18–22% organic growth. The 2024 take-private of R1 RCM by TowerBrook and CD&R cleared at $8.9B, or 14.3x EBITDA — and that was at the peak of healthcare-software exuberance, before Claritev's collapse. The private comps are tighter still: Cotiviti's KKR-led recap in February 2024 valued the company at ~$11B on roughly $1.5B of revenue (a ~7x multiple, before margin assumptions), and Cotiviti's 2025 acquisition of Edifecs came in at 'just over $3B' for a much smaller, less differentiated asset.

Reuters reported that prospective buyers are explicitly weighing whether AI-native competitors could 'ultimately perform many of the same functions more cheaply,' a question Lyric itself is trying to answer by embedding the Lyric42 orchestration layer and adding Concert's AI payment-accuracy tools. The risk is not theoretical: Claritev — formerly MultiPlan, the closest large-cap peer in cost management — fell about 80% between September 2025 and May 2026 and now trades near $38 with a roughly $645M market cap, against revenue in the high-$200M per quarter range and persistently negative GAAP earnings. Its 52-week range of $11.50 to $74.07 illustrates how violently the market is repricing legacy payment-integrity economics.

Lyric is payer-side software, not provider-side RCM, which is what differentiates it from Waystar and the now-private [R1 RCM]. Its upstream is the U.S. health-plan universe — UnitedHealth, Elevance, CVS/Aetna, Humana, Cigna and the Blues — which the company says is nine of the top 10 already on the platform. Its downstream is the broader payment-integrity stack: data, clinical-policy content, post-pay recovery vendors and AI coding/clinical-validation tools (Codoxo, Cohere Health, Availity are adjacent). Lyric itself is plugging Concert into the Lyric42 platform to defend that adjacencies from being disintermediated by AI-native entrants.

Healthcare-software exits are a meaningful share of the PE exit pipeline in 2026, and Lyric is the highest-profile current process. TPG's own Q2 2026 results — reported Aug 4, 2026 — pointed to record first-half performance with AUM of $327B and fee-related revenue up 27%, so the firm has flexibility to walk if bids come in below 20x. But the harder test is for sellers who cannot wait: Cotiviti (KKR/Veritas), the Edifecs legacy (TA/Francisco Partners still running off positions), and the next wave of payer-software and RCM sponsors all need a Lyric print to anchor their own marketing. If the deal lands near $5B, the cohort gets a fresh comp; if it slips to 15–17x, the pressure shifts to every other seller to either accept a haircut or hold.

Near term (days to quarters): the first round of indicative bids from JPMorgan will reveal whether strategic buyers (likely UnitedHealth Group/Optum, Elevance, large payers, and strategic PE) are willing to stretch above the public-comp range. AI-native payment-integrity challengers — including well-funded entrants that have not yet been publicly priced — are the lever buyers will use to compress the ask. Watch whether TPG accepts a 17–19x compromise, walks, or runs a structured secondary to extend the hold. The reported AI-disruption concern is a negotiating position today; it becomes a thesis only if a credible AI-native vendor can demonstrate payer-grade accuracy at a fraction of the seat-plus-transaction pricing.

Long term (1–3 years): if AI does disintermediate the legacy edit-and-review workflow, the seat-plus-transaction pricing model Lyric and Cotiviti run on will compress and the next round of comps will be closer to 10–12x EBITDA — closer to where Waystar trades today on revenue than on EBITDA. If AI instead becomes a feature inside incumbent platforms, Lyric's Concert acquisition positions it to defend the 20x range. The structural winners are likely the payers themselves — vertical integration of payment-integrity into the claims system, which is the UnitedHealth Group/Optum playbook — and the AI-native vendors that can win at the workflow level. The structural losers are the legacy, rules-based vendors without an AI roadmap. For investors, the read-through to public peer Waystar is that growth justifies its premium today; for Claritev it is that the public market is not yet convinced legacy payment-integrity deserves a multiple anywhere near Lyric's ask.